Abstract:UBackground: The bromodomain and extra-terminal proteins (BET), in particular BRD4, has recently emerged as a potential therapeutic target for the treatment of many human disorders such as cancer, inflammation, obesity and cardiovascular disease, which draw more and more attention to discover potent BRD4 inhibitors in the past years. In this article, we described the discovery process of an entirely new chemotype of BRD4 inhibitors. Methods: A fragment-based drug discovery strategy was employed in attempting to find a novel chemotype of BRD4 inhibitors. Thus, the potential hits were firstly identified by docking study with KAc binding pocket and AlphaScreen assay. Then the elected hit was further structurally optimized based on the interaction revealed by the docking study and the Structure-Activity Relationship (SAR). Results: A 1-(2-hydroxyphenyl)ethan-1-one fragment was first identified as an efficient hit to BRD4 with a weak inhibition activity and high ligand efficiency (IC50 = 8.9 mu M LE > 0.5) based on virtual screening and biochemical assay. Then, two-rounds optimization of the hit by a fragment-based drug discovery approach enabled the discovery of a potent BRD4 inhibitor 9, which exhibit nanomolar potency in biochemical assays (IC50 = 0.18 mu M). Conclusion: The title compounds displayed potent inhibitory activity to BRD4, implying acetophenone core is an effective KAc residue mimic, suggesting acetophenone derivatives as a new chemotype may be promising for developing novel BRD4 inhibitors.

Drug Discovery of Acetophenone Derivatives As BRD4 Inhibitors

Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria Sp. NH-F6.

Discovery of Novel Coumarin Derivatives As Potent and Orally Bioavailable BRD4 Inhibitors Based on Scaffold Hopping

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Drug Discovery Targeting Bromodomain-Containing Protein 4

Design, Synthesis and Biological Evaluation of Novel 6-Phenyl-1,3a,4,10b-tetrahydro-2h-benzo[c]thiazolo[4,5-e]azepin-2-one Derivatives As Potential BRD4 Inhibitors.

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Discovery Of 3,5-Dimethylisoxazole Derivatives As Novel, Potent Inhibitors For Bromodomain And Extraterminal Domain (Bet) Family

Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.

Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia

Discovery of the Natural Product 3',4',7,8-Tetrahydroxyflavone As a Novel and Potent Selective BRD4 Bromodomain 2 Inhibitor.

Development of 7-Methylimidazo[1,5-a]pyrazin-8(7h)-one Derivatives As a Novel Chemical Series of BRD4 Inhibitors

Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization and Biological Evaluation.

Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives As Potent and Second Bromodomain (Bd2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

Fragment-based Drug Discovery of 2-Thiazolidinones As Inhibitors of the Histone Reader BRD4 Bromodomain.

Combined Pharmacophore Models As Virtual Screening Protocol Against BRD4(1) Inhibitor

Design, Synthesis and Biological Evaluation of Imidazolopyridone Derivatives As Novel BRD4 Inhibitors.

Development of 4,5-Dihydro-benzodiazepinone Derivatives As A New Chemical Series of Brd4 Inhibitors

Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases

Design, Synthesis and Biological Evaluation of Dihydroquinoxalinone Derivatives As BRD4 Inhibitors.